New hope for liver cancer patients who run out of options
NCT ID NCT07310173
Summary
This study is testing a new drug called AST-3424 for people with advanced liver cancer that has gotten worse despite treatment with modern immunotherapy drugs. It aims to see if this new drug can help patients live longer. Researchers will compare it directly to another available treatment, regorafenib, to find out which is more effective.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing Tianyinshan Hospital
RECRUITINGNanjing, Jiangsu, 211102, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.